Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/07/2026			Après clôture 00:08:00
133,21 ^USD	-0,80%		130,17	-2,28%

16/07	Kalshi va autoriser les paris sur les essais cliniques et les décisions de la FDA	RE
15/07	Marchés africains : les facteurs à suivre le 15 juillet	RE

Autres langues

16/07	Kalshi to allow bets on clinical trials, FDA decisions
15/07	African markets - factors to watch on July 15
14/07	Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
08/07	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
08/07	Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
06/07	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
03/07	Trial for Ebola treatment starts in DR Congo
02/07	Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease
02/07	Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
30/06	Africa CDC seeks $18 million in urgent support for Ebola drug trials in DRC
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Growth-Defensive Index
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell Top 200 Growth Benchmark
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 3000E Growth Benchmark
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 3000 Growth Benchmark
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Dynamic Index
29/06	Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Growth Benchmark
25/06	Major deals involving US drugmakers and biotechs over the past decade
24/06	Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer
24/06	Gilead Gets FDA Approval for Treatment for Aggressive Form of Breast Cancer
24/06	Health Care Up on Rotation Into Beaten-Down Sectors -- Health Care Roundup
24/06	U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
24/06	Gilead Sciences, Inc. Announces FDA Approval Of Trodelvy for First-Line Treatment Of Metastatic Triple-Negative Breast Cancer
23/06	US provides Ebola treatment for outbreak in Congo, bringing trials closer
23/06	Gilead Sciences Announces European Commission Approval for Trodelvy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
23/06	Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment